Strong Results Start
With Strong Settings

Adjusting Insulin Delivery Every
5 Minutes

Omnipod® 5 proactively helps correct for highs, protect from lows, and updates automated insulin delivery with every Pod change to adapt to your patient’s dynamic insulin needs1-3

Omnipod 5 chart of bolus levels and autocorrection points used at NSM Omnipod 5 chart of bolus levels and autocorrection points used at NSM

3 Practical Tips to Strengthen Omnipod 5 Settings

1. Initial Basal Settings

Starting with the right initial basal settings will set your patients up for success.

  • For patients transitioning from MDI, ensure programmed basal rates account for ~50% of total daily insulin (TDI) (basal + bolus)
HCP with mother and daughter in exam room looking at Pod on daughter's arm HCP with mother and daughter in exam room looking at Pod on daughter's arm

TDI is key to how Omnipod 5 calculates the automated insulin delivery rate, which updates with every Pod change.

By strengthening Target Glucose and user-initiated insulin settings, you can impact TDI. By increasing the TDI, the system can deliver more automated insulin.

2. Automated Insulin Setting

Target Glucose is the only setting that directly impacts the aggressiveness of the Omnipod 5 algorithm.

  • There are five Target Glucose options for flexibility. Consider the 110 mg/dL Target Glucose to increase TIR4
  • Consider higher Target Glucose or using the Activity feature during consistent times of greater risk for hypoglycemia
Orange icon arrow point up with the words "12% MORE TIR" in black inside the arrow Orange icon arrow point up with the words "12% MORE TIR" in black inside the arrow

Real-world T1D users increased TIR by nearly 12% by switching to the lowest Target Glucose setting with no clinically meaningful impact on time below range.5

3. User-Initiated Insulin Settings

Strengthen SmartBolus Calculator settings so when your patients bolus they get the insulin they need.6

Bolus settings affect total daily insulin

Adjustments to any of the settings below will impact TDI, which is used to calculate the automated insulin delivery rate- by increasing the TDI, the system can deliver more automated insulin.

bread icon

Strengthen Insulin-to-Carb Ratios (ICRs) (10-25%)6

Omnipod 5 reduces insulin when glucose is trending down or below target, which can leave little to no IOB leading up to mealtimes. With little IOB before meals, users may benefit from a stronger insulin/to/carb ratio.

A check mark inside of a circle inside of a square, all outlined in the color orange

Strengthen Correction Factors

Correction Factor is only used for user-initiated correction boluses when the user enters a glucose reading or taps “Use Sensor”. Consider strengthening if a pattern of hyperglycemia persists following correction doses.

Icon of an orange arrow pointing up

Adjust Correct Above setting when changing to lower Target Glucose

Correct Above is the threshold at which the SmartBolus Calculator will calculate a correction dose during a user-initiated bolus. Consider making Correct Above the same as the user’s Target Glucose to increase bolus amounts.

Icon

Toggle OFF Reverse Correction

Turning OFF Reverse Correction will ensure that users receive their full bolus dose for meals.

Icon of a clock outlined in orange

Lower hours of Duration of Insulin Action

IOB is calculated from both user-initiated boluses and insulin delivered by the algorithm for autocorrections. Duration of Insulin Action is ONLY used to calculate IOB from user-initiated boluses.

HCP nurse with patient looking at a laptop screen in amazement HCP nurse with patient looking at a laptop screen in amazement

Find the right balance between automated and user-initiated insulin by lowering Target Glucose and strengthening SmartBolus Calculator settings.

Learn more about
personalizing settings

“Practical considerations for using the Omnipod 5 Automated Insulin Delivery System:
Clinical experience from the United States and Europe”

Download Publication Here
A headshot of Cari Berfet A headshot of Cari Berfet

In Diabetes, Obesity and Metabolism Volume 27, Issue 6 Jun 2025

By: Cari Berget, et al.

The authors provide a series of clinical vignettes illustrating advanced cases related to the initiation and ongoing optimization of insulin therapy using the Omnipod 5 system, including how to personalize settings and optimize glycemic outcomes in a variety of clinical circumstances.

If you are unable to find the information you are seeking or require additional information, please
contact us.

References:

1. Brown S, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-month Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
2. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9 yrs) as measured by CGM: ST = 39.4%, 3-month Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-month Omnipod 5 = 2.46%, P=0.0204. Results measured by CGM. Study funded by Insulet.
3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL as measured by CGM: ST = 54%, 3-month Omnipod 5 = 34%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-month Omnipod 5 = 0.2%.
4. Berget C, Annan SF, Biester T, et al. Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025;1‐11.
5. Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with type 1 diabetes aged 2+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (P<0.05). Median time <70 mg/dL +0.23% (P<0.05). Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Insulet Data on File. 05.15.25. RF-042025-00013
6. Berget C et al. Clinical Diabetes. 2022;40(2):168-184

Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information.

INS-OHS-06-2025-00020 V2.0